AXDX vs. OMIC, TLIS, RPID, TBIO, PRE, EKSO, NEPH, TXMD, BFRG, and CPIX
Should you be buying Accelerate Diagnostics stock or one of its competitors? The main competitors of Accelerate Diagnostics include Singular Genomics Systems (OMIC), Talis Biomedical (TLIS), Rapid Micro Biosystems (RPID), Telesis Bio (TBIO), Prenetics Global (PRE), Ekso Bionics (EKSO), Nephros (NEPH), TherapeuticsMD (TXMD), Bullfrog AI (BFRG), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "medical" sector.
Accelerate Diagnostics (NASDAQ:AXDX) and Singular Genomics Systems (NASDAQ:OMIC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
Accelerate Diagnostics presently has a consensus price target of $1.00, suggesting a potential downside of 35.06%. Singular Genomics Systems has a consensus price target of $0.63, suggesting a potential upside of 67.79%. Given Singular Genomics Systems' higher probable upside, analysts clearly believe Singular Genomics Systems is more favorable than Accelerate Diagnostics.
Accelerate Diagnostics has higher revenue and earnings than Singular Genomics Systems. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Singular Genomics Systems, indicating that it is currently the more affordable of the two stocks.
Accelerate Diagnostics has a net margin of -452.28% compared to Singular Genomics Systems' net margin of -3,863.90%. Accelerate Diagnostics' return on equity of 0.00% beat Singular Genomics Systems' return on equity.
Accelerate Diagnostics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Singular Genomics Systems has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.
Accelerate Diagnostics received 341 more outperform votes than Singular Genomics Systems when rated by MarketBeat users. Likewise, 63.10% of users gave Accelerate Diagnostics an outperform vote while only 46.43% of users gave Singular Genomics Systems an outperform vote.
17.1% of Accelerate Diagnostics shares are owned by institutional investors. Comparatively, 65.8% of Singular Genomics Systems shares are owned by institutional investors. 43.6% of Accelerate Diagnostics shares are owned by insiders. Comparatively, 22.2% of Singular Genomics Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Accelerate Diagnostics had 2 more articles in the media than Singular Genomics Systems. MarketBeat recorded 4 mentions for Accelerate Diagnostics and 2 mentions for Singular Genomics Systems. Singular Genomics Systems' average media sentiment score of 1.88 beat Accelerate Diagnostics' score of 0.55 indicating that Singular Genomics Systems is being referred to more favorably in the news media.
Summary
Accelerate Diagnostics beats Singular Genomics Systems on 10 of the 18 factors compared between the two stocks.
Get Accelerate Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Accelerate Diagnostics Competitors List
Related Companies and Tools
